Tokyo-based pharmaceutical company founded in May 2024 that licenses medicines from US and European biotech companies and develops them for Japan and Asia. It combines clinical development, regulatory work and commercialization to address the absence of overseas treatments in these markets. Its neuroscience work includes an oral cannabidiol drug program for epilepsy through a June 2025 co-development and exclusive regional licensing agreement with Avata Biosciences.
